样式: 排序: IF: - GO 导出 标记为已读
-
Goodnight Moon: The (not so) mystical effect of folklore and superstitions on cardiac transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-13 Michaela Asher,Amit Iyengar,David Rekhtman,Joyce Jiang,Cindy Song,Noah Weingarten,Max Shin,Lindsay Nitsche,Constantine D Mavroudis
BACKGROUND The effect of Friday the 13th and Full Moons on cardiac transplantation is unknown. We investigated the impact of these superstitious events on recipient and donor qualities, complications, survival, and volume. METHODS All adult transplants from 2013-2023 in the United Network for Organ Sharing database were retrospectively reviewed. Friday the 13th recipients were compared to Adjacent
-
Improving the odds: reducing diagnostic uncertainty with bronchoalveolar lavage cytokine profiling. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-11 Daniel R Calabrese,Lorriana E Leard
-
"Surveillance without scars": The quest for noninvasive detection of cardiac allograft rejection. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-11 Ameesh Isath,Mandeep R Mehra
-
Primary graft dysfunction, dysbiosis, and innate immune activation after lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-11 Adam G Stewart,Daniel C Chambers
-
Dosing of Apixaban with Left Ventricular Assist Devices: A Need for Greater Clarity. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-11 Ajith Nair,Palak Shah
-
Equity and center variation in listing status exceptions for pediatric heart transplant candidates since pediatric review board implementation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-09 Lydia K Wright,Stacey Culp,Robert J Gajarski,Deipanjan Nandi
BACKGROUND A pediatric national heart review board (NHRB) and exception guidance document to standardize decision-making were implemented in 2021 to reduce variability and ensure equity in status exceptions for pediatric candidates. We evaluated the hypothesis that these changes decreased center variability and racial disparities within the granted exceptions. METHODS Guidance document and pediatric
-
Harnessing Mesenchymal Stem Cells for Improving Lung Transplant Outcomes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-06 Ghandi F Hassan,Jen Alexander-Brett
-
Measuring the Seemingly Unmeasurable: New Metrics in Heart Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-06 Jeffery Teuteberg
-
Emerging role of circulating piRNAs in the diagnosis of heart transplant rejection. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-06 Lorena Pérez-Carrillo,Irene González-Torrent,Isaac Giménez-Escamilla,Marta Delgado-Arija,Carlota Benedicto,Manuel Portolés,Estefanía Tarazón,Esther Roselló-Lletí
BACKGROUND Liquid biopsy offers a potential alternative to decrease or eliminate endomyocardial biopsy (EMB) for diagnosing allograft rejection. piRNAs are novel and promising disease biomarkers for their intrinsic characteristics such as stability in body fluids; however, their role in allograft rejection remains unexplored. METHODS A training set based on small RNA sequencing technology was performed
-
Breathing New Life: Expansion of ECMO as a bridge to Lung Transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-06 Sahar A Saddoughi
-
Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-05 Mardi Gomberg-Maitland,David B Badesch,J Simon R Gibbs,Ekkehard Grünig,Marius M Hoeper,Marc Humbert,Grzegorz Kopeć,Vallerie V McLaughlin,Gisela Meyer,Karen M Olsson,Ioana R Preston,Stephan Rosenkranz,Rogerio Souza,Aaron B Waxman,Loïc Perchenet,James Strait,Aiwen Xing,Amy O Johnson-Levonas,Alexandra G Cornell,Janethe de Oliveira Pena,H Ardeschir Ghofrani
BACKGROUND This analysis compared effects of the activin signaling inhibitor, sotatercept, across pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). METHODS Pooled data from PULSAR (N=106; NCT03496207) and STELLAR (N=323; NCT04576988) were analyzed using two different CI thresholds, < and ≥ 2.0 L/min/m2 or 2.5 L/min/m2. Median differences in change from baseline
-
The Transformation of Transplant Medicine with Artificial Intelligence-Assisted Tacrolimus Dosing. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Lorriana E Leard,Catherine Blebea
-
Pump Exchange for Major Device Related Infection in Patients Receiving a Durable Left Ventricular Assist Device. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Sophie R Persaud,Michael Pienta,Donald S Likosky,Francis D Pagani
BACKGROUND Device-related infection (DRI) remains a cause of morbidity and mortality following durable left ventricular assist device (dLVAD) implantation. We evaluated outcomes following pump exchange (PE) for DRI following dLVAD implantation. METHODS Forty-nine patients underwent PE between 1/2007 and 12/2022 for major DRI. Outcomes included survival, incidence of subsequent DRI, and proportion of
-
A gift of life, not immortality: Evaluation of a strategy of heart transplant listing in the older patient with advanced heart failure. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Thomas M Cascino,Carol Ling,Donald S Likosky,Francis D Pagani,Jennifer Cowger
Patients 65 years of age or older represent the fastest-growing demographic group added to the U.S. heart transplant (HT) list. While post-HT outcomes appear acceptable, immortal time bias is introduced if adverse outcomes that occur while waiting for HT are not considered. Recent durable left ventricular assist device (dLVAD) technological innovations have engendered the question of whether this patient
-
Refining the Gold Standard: Volume Calibration Methods for Right Ventricular Pressure-Volume Loops. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Brian A Houston
-
Basiliximab Induction Immunosuppression and Lung Transplant Outcomes: Propensity Analysis in a Multicenter Cohort. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Jeeyon G Rim,Anne S Hellkamp,Megan L Neely,John M Reynolds,John A Belperio,Marie Budev,Lerin Eason,Courtney W Frankel,Shaf Keshavjee,Jerry Kirchner,Lianne G Singer,Pali D Shah,Laurie D Snyder,S Samuel Weigt,Scott M Palmer,Jamie L Todd
BACKGROUND Basiliximab induction immunosuppression is increasingly employed in lung transplant recipients despite limited prospective evidence to support its use in this population. We sought to determine the relationship between basiliximab induction and development of acute rejection, chronic lung allograft dysfunction, and other clinically relevant outcomes in a multicenter lung transplant cohort
-
Ten-Year Report on the First Patient with HeartMate 3 Left Ventricular Assist Device. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-04 Jasmin S Hanke,Günes Dogan,Arjang Ruhparwar,Jan D Schmitto
-
The Prognostic Value of Single and Repeated ≥10% FEV1 Declines for Chronic Lung Allograft Dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-03 Kimberly Lu,Miranda C Bradford,Xuanshuang Wang,Ted Liu,Chelsea Schmitz,Erika D Lease,Siddhartha Kapnadak,Ramsey Hachem,Kathleen J Ramos,Eric D Morrell
There is a paucity of data reporting the positive and negative predictive values (PPV, NPV) of acute declines in lung function on chronic lung allograft dysfunction (CLAD). We sought to define the predictive ability of single or repeated FEV1 declines for at least 3 weeks on the development of CLAD or death by 1-year. We analyzed 340 subjects with at least 3 years of follow-up data from two lung transplant
-
Severe primary graft dysfunction in heart transplant recipients using donor hearts after circulatory death: United States experience. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-28 Peter D Cho,Samuel T Kim,Hedwig Zappacosta,John P White,Stephanie McKay,Reshma Biniwale,Abbas Ardehali
OBJECTIVE This study compares the incidence of severe Primary Graft Dysfunction (PGD) in a contemporaneous cohort of donors after circulatory death (DCD) and brain death (DBD) heart transplant recipients. METHOD The United Network for Organ Sharing database was queried for isolated adult heart transplant recipients from 9/2023 to 6/2024. Heart recipients were stratified based on the organ donation
-
Impact of cardiopulmonary resuscitation on donation after circulatory death heart transplantation: A United Network for Organ Sharing registry analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-28 Nidhi Iyanna,Umar Nasim,Ander Dorken-Gallastegi,Nicholas R Hess,Mohamed Abdullah,Gavin W Hickey,Mary E Keebler,Edward T Horn,Yeahwa Hong,David J Kaczorowski
BACKGROUND The criteria for evaluating donations after circulatory death (DCD) heart allografts, particularly donor cardiopulmonary resuscitation (CPR) status, remains underexplored. This study evaluates the impact of donor CPR on post-transplant outcomes in DCD heart transplants. METHODS The UNOS registry was queried to analyze adult recipients who underwent DCD heart transplantation between 1/1/2019
-
Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: subgroup analysis of the phase 3 randomized SOLSTICE study. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-27 Emily A Blumberg,Oliver Witzke,Mark Harber Mbbs,Michael G Ison,Faouzi Saliba,Nassim Kamar,Aimee K Sundberg,Joan Gu,Deepali Kumar,Ricardo M La Hoz
BACKGROUND In the phase 3 SOLSTICE study (NCT02931539), maribavir was superior to investigator-assigned therapy (IAT) for confirmed cytomegalovirus viremia clearance at study week 8 in hematopoietic cell/solid organ transplant (HCT/SOT) recipients. We report additional efficacy and safety analyses from the SOT subgroup. METHODS Eligible solid organ transplant recipients (n=211) received maribavir 400
-
High-dimensional tissue profiling of immune cell responses in chronic lung allograft dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-26 Saskia Bos,Bethany Hunter,David McDonald,George Merces,Georgia Sheldon,Pauline Pradère,Joaquim Majo,Julian Pulle,Arno Vanstapel,Bart M Vanaudenaerde,Robin Vos,Andrew J Filby,Andrew J Fisher
PURPOSE The immunological drivers of chronic lung allograft dysfunction (CLAD), the major barrier to long-term survival after lung transplantation, are poorly understood at a tissue level. Tissue imaging using mass spectrometry with laser ablation of regions of interest offers single-cell resolution of distinct immune cell populations and their spatial relationships and may improve our understanding
-
Waitlist mortality for patients with cardiac allograft vasculopathy under the 2018 OPTN donor heart allocation system. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-26 Bernard S Kadosh,Suhani S Patel,Sharnendra K Sidhu,Allan B Massie,Stephanie Golob,Randal I Goldberg,Alex Reyentovich,Nader Moazami
BACKGROUND In the 2018 Organ Procurement and Transplantation Network donor heart allocation system, patients listed for re-transplantation due to cardiac allograft vasculopathy (CAV) are assigned to Status 4 unless hemodynamic criteria are met. We aim to examine waitlist outcomes of CAV patients among adult heart transplant candidates. METHODS We examined waitlist mortality stratified by CAV and waitlist
-
Tacrolimus, cyclosporine, and lung transplantation in the "real world". J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-23 Kieran Halloran
-
Chronic Thromboembolic Pulmonary Hypertension and Cancer: a true relationship, but one likely beyond coagulation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-23 Christian Gerges,Irene M Lang
-
Nr4a1: A multilevel target to overcome PGD in lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-20 Cedric Vanluyten,Robin Vos,Laurens J Ceulemans
-
Donor-derived cell-free DNA as a new biomarker for cardiac allograft rejection: A prospective study (FreeDNA-CAR). J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-20 Marta Jiménez-Blanco,Maria Generosa Crespo-Leiro,Maria Dolores García-Cosío Carmena,Manuel Gómez Bueno,Raquel López-Vilella,Carlos Ortiz-Bautista,Marta Farrero-Torres,Isabel Zegrí-Reiriz,Beatriz Díaz-Molina,Elena García-Romero,Diego Rangel-Sousa,Nahikari Salterain,Iris Garrido Bravo,Javier Segovia-Cubero
BACKGROUND There is a long-standing need for a noninvasive biomarker that allows monitoring of cardiac allograft rejection, avoiding the need for periodic endomyocardial biopsies (EMB). METHODS Multicenter, observational, prospective study, performed between 2019 and 2023 (NCT04973943). All patients underwent 7 per-protocol surveillance EMB during the first postheart transplantation year. Donor-derived
-
Mechanical circulatory support and post-transplant infections: Is temporary MCS really riskier? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-20 Saima Aslam
-
Extended duration of ex-vivo perfusion is associated with worse survival in donation after circulatory death heart recipients: A national database analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-20 Ruby Singh,George Olverson,Kristian Punu,Adham Makarem,Chijioke C Chukwudi,Sarah A Brownlee,Antonia Kreso,Seyed Alireza Rabi,Eriberto Michel,Gregory D Lewis,David A D'Alessandro,Asishana A Osho
BACKGROUND The impact of duration of ex-vivo heart perfusion (EVHP) on patient outcomes following donation after circulatory death (DCD) heart transplantation has not been established. METHODS Adult first-time DCD heart transplants using EVHP were identified in the Organ Procurement & Transplant Network database (12/2019-09/2023). Total out of body time (OBT) was dichotomized based on perfusion duration
-
Aortic insufficiency in the patient on contemporary durable left ventricular assist device support: Comment. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-12-01 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Liran Levy,Sajad Moshkelgosha,Ella Huszti,Stella Wang,Sarah Hunter,Chen Yang Kevin Zhang,Rasheed Ghany,Shaf Keshavjee,Lianne G Singer,Jussi Tikkanen,Stephen Juvet,Tereza Martinu
BACKGROUND Surveillance bronchoscopies with bronchoalveolar lavage (BAL) and transbronchial biopsies (TBB) are primarily used to detect acute cellular rejection (ACR) or infection in lung transplant (LTx) recipients. We previously identified a BAL protein signature associated with chronic lung allograft dysfunction (CLAD) or death/retransplant in patients with stable minimal (grade A1) ACR. This present
-
Predictors of donation after circulatory death lung utilization and allograft survival. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Isaac S Alderete,Arya Pontula,Cathlyn K Medina,Samantha E Halpern,Jacob A Klapper,Megan L Neely,Laurie Snyder,Matthew G Hartwig
BACKGROUND Understanding donor factors associated with successful lung transplantation (LTx) following donation after circulatory death (DCD) is important in optimizing donor management. In this study, we examined critical care and ventilatory factors associated with DCD LTx and allograft survival using a unique detailed donor management database. METHODS The Donor Management Goals national registry
-
Promise of a new day - will EVLP fulfill its therapeutic potential? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Srineil Vuthaluru,Aleem Siddique
-
Donor sequence number is not associated with worse lung transplant outcomes regardless of transplant center case volume. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Alfred J Casillan,Emily L Larson,Alice L Zhou,Jessica M Ruck,Armaan F Akbar,Allan B Massie,Dorry L Segev,Christian A Merlo,Errol L Bush
BACKGROUND Potential lung transplantation (LTx) recipients are assigned a donor sequence number (DSN) based on their position on the match list. Since a higher DSN offer has already been declined for other recipients, some providers may assume that a high DSN connotates poorer allograft quality. This study evaluated the association between DSN and outcomes, the correlation between transplant program
-
A Tale of Two Indications for EVLP. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Kenneth R McCurry,Toshihiro Okamoto
-
Association of agonal phase duration with heart utilization and post-transplant outcomes in donation after circulatory death heart transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-19 Yeahwa Hong,Nicholas R Hess,Ander Dorken-Gallastegi,Nidhi Iyanna,Gavin W Hickey,Michael A Mathier,Dennis M McNamara,Mary E Keebler,Edward T Horn,David J Kaczorowski
BACKGROUND This study evaluates the impact of the agonal phase and related hemodynamic measures on post-transplant outcomes and heart utilization in donation after circulatory death (DCD) heart transplantation. METHODS United Network for Organ Sharing registry was queried to analyze adult recipients who underwent isolated DCD heart transplantation between January 1, 2019 and September 30, 2023. The
-
Therapeutic Plasma Exchange is Associated with Increased Survival in Heart Transplant Recipients Experiencing Severe Primary Graft Dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-17 Yosef Manla,David H Chang,Jignesh Patel,Avani Kanugo,Andriana Nikolova,Evan Kransdorf,Lawrence S Czer,Lily Stern,Michele Hamilton,Michelle Kittleson,Jon A Kobashigawa
BACKGROUND Primary graft dysfunction (PGD) remains the leading cause of 30-day mortality post-heart transplantation (HTx). HTx recipients experiencing severe PGD have been found to have high levels of circulating proteins associated with PGD occurrence and post-HTx survival. Whether treating these patients with therapeutic plasma exchange (TPE) can attenuate ongoing immunological and inflammatory processes
-
Lung allograft dysbiosis associates with immune response and primary graft dysfunction. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-17 Nathaniel C Nelson,Kendrew K Wong,Ian J Mahoney,Tahir Malik,Darya Rudym,Melissa B Lesko,Seema Qayum,Tyler C Lewis,Stephanie H Chang,Justin C Y Chan,Travis C Geraci,Yonghua Li,Prerna Pamar,Joseph Schnier,Rajbir Singh,Destiny Collazo,Miao Chang,Yaa Kyeremateng,Colin McCormick,Sara Borghi,Shrey Patel,Fares Darawshy,Clea R Barnett,Imran Sulaiman,Matthias C Kugler,Shari B Brosnahan,Shivani Singh,Jun-Chieh
BACKGROUND Lower airway enrichment with oral commensals has been previously associated with severe primary graft dysfunction (PGD) after lung transplantation (LT). We aimed to determine whether this dysbiotic signature is present across all PGD severity grades and whether it is associated with a distinct host inflammatory endotype. METHODS Lower airway samples from 96 LT recipients were used to evaluate
-
Peak VO2: An old-school prognostic metric for all heart failure seasons. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-17 Paolo C Colombo,Melana Yuzefpolskaya
-
Can sinoatrial reinnervation improve survival after heart transplantation? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-16 Anders H Christensen
-
Apixaban plasma levels in patients with HeartMate 3 support. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 Charlotte J Van Edom,Bjorn Cools,Walter Droogné,Steven Jacobs,Joeri Van Puyvelde,Dirk Vlasselaers,Thomas Vanassche,Bart Meyns
BACKGROUND Apixaban is increasingly used instead of vitamin K antagonists (VKAs) for long-term anticoagulation during HeartMate 3 (HM3) support. However, data on its pharmacokinetics in this context is lacking. We present real-world data on apixaban levels and outcomes in adult and pediatric HM3 patients, and evaluate our dosing strategy based on plasma sampling. METHODS Since June-2023, all new HM3
-
Advancing patient-centered metrics for heart transplantation: The role of days alive and outside the hospital. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 J'undra N Pegues,Reem M Fawaz,Kinka M Kimfon,Hechuan Hou,Pierre-Emmanuel Noly,Thomas M Cascino,Robert B Hawkins,James W Stewart Ii,Keith Aaronson,Jennifer Cowger,Francis D Pagani,Donald S Likosky,
BACKGROUND Heart transplantation (HT) survival and waitlist times are established outcome metrics. Patient-centered HT outcomes are insufficiently characterized. This study evaluates the role of days alive and outside the hospital (DAOH) as a candidate patient-centered HT performance measure. METHODS The study cohort included Medicare beneficiaries undergoing HT (July 2008-December 2017). The percent
-
Navigating surgical risks: The impact of BMI outliers on pulmonary endarterectomy outcomes. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-15 Olaf Mercier
-
Factors associated with waitlist clinical deterioration among United States lung transplant recipients under the continuous distribution system. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-12 Tatenda G Mupfudze,Chelsea J Hawkins,Samantha Weiss,Rebecca R Goff,Grace R Lyden,Erika D Lease,Matthew Hartwig,Maryam Valapour
BACKGROUND Lung continuous distribution (CD), implemented on March 9, 2023, changed the calculation and relative importance of medical urgency and post-transplant survival in prioritizing candidates for transplant. We aimed to identify factors associated with waitlist clinical deterioration and change in expected post-transplant survival from listing to transplant in the current system. METHODS We
-
Xenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-12 Nicholas B Bechet,Aybuke Celik,Margareta Mittendorfer,Qi Wang,Tibor Huzevka,Gunilla Kjellberg,Embla Boden,Gabriel Hirdman,Leif Pierre,Anna Niroomand,Franziska Olm,James D McCully,Sandra Lindstedt
BACKGROUND Ischemia-reperfusion injury (IRI) plays a crucial role in the development of primary graft dysfunction (PGD) following lung transplantation. A promising novel approach to optimize donor organs before transplantation and reduce the incidence of PGD is mitochondrial transplantation. METHODS In this study, we explored the delivery of isolated mitochondria in 4 hours ex vivo lung perfusion (EVLP)
-
Impact of donor age ≥65 years on graft survival in large lung transplant cohorts. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-12 Andrei M Darie,Bronwyn J Levvey,Helen V Shingles,Miranda A Paraskeva,Kovi Levin,Samantha L Ennis,Michael Perch,Glen P Westall,Gregory I Snell
BACKGROUND Although the demand for allografts continuously surpasses the supply, the majority of lungs offered for transplant are declined based on various factors, including donor age. This in turn sustains the wait-list mortality of patients with end-stage pulmonary disease. METHODS In this single-center, observational cohort study, we investigated the impact of donor age on graft survival. We additionally
-
Risk assessment models and survival in pulmonary arterial hypertension: a SPAHR analysis. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-11 Clara Hjalmarsson,Tanvee Thakur,Tracey Weiss,Erik Björklund,Joanna-Maria Papageorgiou,Göran Rådegran,Stefan Söderberg,Håkan Wåhlander,Dominik Lautsch,Barbro Kjellström
BACKGROUND Multicomponent improvement (MCI) is a novel endpoint for predicting survival in patients with pulmonary arterial hypertension (PAH), included in the sotatercept clinical program. For the first time, we investigated the prognostic value of MCI, ESC/ERS 4-strata risk (4SR) assessment, and the non-invasive French risk stratification score (FRS), for predicting survival in PAH patients in Sweden
-
Toward early prediction of chronic allograft dysfunction using molecular biomarkers. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-08 Peter T Bell,Daniel C Chambers
-
Optimized surveillance frequency for low bone mineral density (BMD) screening using dual-energy X-ray absorptiometry (DXA) in patients after lung transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-07 Ronnie Sebro,Mahmoud Elmahdy
BACKGROUND Approximately 2,700 lung transplants are performed annually in the United States. These patients are at increased risk of developing low bone mineral density (BMD) (osteopenia/osteoporosis) and subsequent fractures. Dual-energy X-ray absorptiometry (DXA) is the most common method used for screening for low BMD; however, the optimal surveillance frequency for low BMD using DXA is unknown
-
A systematic review of reporting and handling of missing data in observational studies using the UNOS database. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-07 William L Baker,Timothy E Moore,Eric Baron,Michelle Kittleson,William F Parker,Abhishek Jaiswal
BACKGROUND Missing data decreasing study power and introducing bias, thereby undermining a registry's ability to draw valid inferences. We evaluated how missing data are reported and addressed in heart transplantation (HT) studies using the United Network for Organ Sharing (UNOS) database. METHODS We conducted a systematic literature search of Medline from January 1, 2018 through August 22, 2023 and
-
Periodic administration of levosimendan as a bridge to transplant : Potiusque sero quam nunquam. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-06 Daniele Masarone,Luigi Falco,Angelo Caiazzo,Claudio Marra,Emilio di Lorenzo
-
Long short-term memory algorithm for personalized tacrolimus dosing: A simple and effective time series forecasting approach post-lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-05 Haruki Choshi,Kentaroh Miyoshi,Maki Tanioka,Hayato Arai,Shin Tanaka,Kazuhiko Shien,Ken Suzawa,Mikio Okazaki,Seiichiro Sugimoto,Shinichi Toyooka
BACKGROUND Management of tacrolimus trough levels (TTLs) influences morbidity and mortality after lung transplantation. Several studies have explored pharmacokinetic and artificial intelligence models to monitor tacrolimus levels. However, many models depend on a wide range of variables, some of which, like genetic polymorphisms, are not commonly tested for in regular clinical practice. This study
-
Could emulated trials play a key role in cardiogenic shock trials? J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-04 Aurore Ughetto,Nicolas Nagot,Clément Delmas
Temporary mechanical circulatory support (tMCS) using extracorporeal life support (ECLS), has been widely implemented in patients with cardiogenic shock (CS), although evidence regarding its efficacy and safety remains unclear. This lack of clarity has recently raised concerns about the role of tMCS in CS management. Conducting randomized controlled trials (RCTs) in the context of CS poses significant
-
Donor age and ischemic time in heart transplantation - implications for organ preservation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-02 Victoria Jernryd,Josef Stehlik,Carsten Metzsch,Lars H Lund,J Gustav Smith,Bodil Andersson,Raquel Perez,Johan Nilsson
BACKGROUND The Organ Care System and Non-ischemic Heart Preservation methods have emerged as significant advancements in heart transplantation, designed to mitigate ischemic injury and extend preservation times. However, their high costs and logistical complexities necessitate strategic utilization. METHODS We evaluated data from 83,761 heart transplants registered in the International Society for
-
The balance of risks: Outcomes associated with mechanical circulatory support after pediatric heart transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-02 Hari Tunuguntla,Aamir Jeewa
-
Early single-center experience with an ex vivo organ care system in pediatric heart transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-11-01 Cathlyn K Medina,Berk Aykut,Lauren E Parker,Neel K Prabhu,Lillian Kang,Ziv Beckerman,Jacob N Schroder,Douglas M Overbey,Joseph W Turek
Pediatric heart transplantation (HTx) faces challenges such as limited donor availability and the need for complex reconstructions, particularly in patients with congenital anomalies. Ex vivo perfusion offers a promising approach to minimize graft ischemic time and potentially expand the donor pool. We report our single-center experience using the TransMedics Organ Care System (OCS) for ex vivo perfusion
-
Utilization and outcomes of nonintubated extracorporeal membrane oxygenation as a bridge to lung transplant. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Alice L Zhou,Maria R Jennings,Armaan F Akbar,Jessica M Ruck,Atharv Oak,Andrew Kalra,Emily L Larson,Alfred J Casillan,Jinny S Ha,Christian A Merlo,Errol L Bush
BACKGROUND Nonintubated extracorporeal membrane oxygenation (ECMO) has been increasingly utilized for patients with severe respiratory failure. Since data on its use as a bridge to lung transplant remain limited, we evaluated its use in a national cohort. METHODS Adult lung-only transplant recipients bridged with ECMO May 4, 2005 to March 8, 2023 in the United Network for Organ Sharing database were
-
Cancer as an independent mortality risk in chronic thromboembolic pulmonary hypertension. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Junichi Nakamura,Ichizo Tsujino,Kohei Masaki,Kazuya Hosokawa,Kouta Funakoshi,Yu Taniguchi,Shiro Adachi,Takumi Inami,Jun Yamashita,Hitoshi Ogino,Masaru Hatano,Nobuhiro Yaoita,Nobutaka Ikeda,Hiroto Shimokawahara,Nobuhiro Tanabe,Kayoko Kubota,Ayako Shigeta,Yoshito Ogihara,Koshin Horimoto,Yoshihiro Dohi,Takashi Kawakami,Yuichi Tamura,Koichiro Tatsumi,Kohtaro Abe
BACKGROUND The management of chronic thromboembolic pulmonary hypertension (CTEPH) has advanced significantly in recent years, thereby improving patient prognosis. However, the impact of cancer on the outcomes of patients with CTEPH under current treatment remains unclear. This study aimed to investigate the prevalence of cancer in patients with CTEPH and determine how comorbid cancer affects their
-
The effect of rewarming ischemia on tissue transcriptome and metabolome signatures: A clinical observational study in lung transplantation. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-30 Jan Van Slambrouck,Shauni Loopmans,Elena Prisciandaro,Annalisa Barbarossa,Phéline Kortleven,Simon Feys,Christelle M Vandervelde,Xin Jin,Ismail Cenik,Karen Moermans,Steffen Fieuws,An-Lies Provoost,Anton Willems,Paul De Leyn,Hans Van Veer,Lieven Depypere,Yanina Jansen,Jacques Pirenne,Arne Neyrinck,Birgit Weynand,Bart Vanaudenaerde,Geert Carmeliet,Robin Vos,Dirk Van Raemdonck,Bart Ghesquière,Johan Van
BACKGROUND In lung transplantation (LuTx), various ischemic phases exist, yet the rewarming ischemia time (RIT) during implantation has often been overlooked. During RIT, lungs are deflated and exposed to the body temperature in the recipient's chest cavity. Our prior clinical findings demonstrated that prolonged RIT increases the risk of primary graft dysfunction. However, the molecular mechanisms
-
Volume calibration with cardiac MRI versus hypertonic saline for right ventricular pressure-volume loops with exercise: Impact on ventricular function and ventricular-vascular coupling. J. Heart Lung Transplant. (IF 6.4) Pub Date : 2024-10-28 Farhan Raza,Chris G Lechuga,Oliver Wieben,Naomi C Chesler
BACKGROUND Right ventricular (RV) pressure-volume (PV) loops require postacquisition volume calibration by cardiac MRI (CMR) or hypertonic saline (HS). We defined the impact of these 2 volume calibration methods on rest-to-exercise ventricular contractility (end-systolic elastance: Ees), arterial afterload (Ea), and coupling (Ees/Ea). METHODS In a prospective study, 82 RV PV-loop datapoints (rest,